A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis FREEDOM (Fracture REduction Evaluation of Denosumab in Osteoporosis Every 6 Months).

Trial Profile

A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis FREEDOM (Fracture REduction Evaluation of Denosumab in Osteoporosis Every 6 Months).

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Jun 2017

At a glance

  • Drugs Denosumab (Primary)
  • Indications Fracture; Postmenopausal osteoporosis; Vertebral fracture
  • Focus Registrational; Therapeutic Use
  • Acronyms FREEDOM
  • Sponsors Amgen
  • Most Recent Events

    • 04 Apr 2017 Combined results of FREEDOM and FREEDOM- extension study (n=794) presented at The 99th Annual Meeting of the Endocrine Society
    • 04 Apr 2017 Results of incidences of vertebral fracture after discontinuation of denosumab treatment in patients from FREEDOM trial and its extension study (n=470) presented at The 99th Annual Meeting of the Endocrine Society
    • 17 Apr 2016 Results of FREEDOM and FREEDOM extension studies presented at the 2016 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top